The URL can be used to link to this page

Anthony Japour Board_And_Committee_Application and ResumeCITY OF MIAMI BEACH BOARD AND COMMITTEE APPLICATION FORM JapourAnthonyJ NAME: First Name Last Name Middle Initial FL33149 HOME ADDRESS : 200 Ocean Drive, #5AMiami Beach Home No./StreetState Apt No.City Zip Code ajjapour@me.com 305-989-4500305-989-4500 PHONE : WorkEmail Address HomeFax Director Business Name: Anthony Japour & Assoc. Medical Position: 200 Ocean Drive, 5A Miami BeachFL33139 Address: State CityZip Code Street Pursuant to City Code section 2-22(4) a and b: Members of agencies, boards, and committees shall be affiliated requirement shall be fulfilled in the following ways: a) an indi months; or b) an individual shall demonstrate ownership/interest Yes Yes Yes circle one): I am now a resident of: South Beach See full resume No 123Please note that only three (3) Please list your preferences in order of ranking [] first choice [] second choice, and [] third choice. choices will be observed by the City Clerks Office. (Regular Boards of City) Choice 1:Health Advisory Committee Choice 2:Art in Public Places Committee Choice 3: Ad Hoc Committee Centennial Celebration Note: If applying for Youth Advisory Board, please indicate your aff 1. Past service on the Youth Center Advisory Board: No Years of Service: if yes, please list the names of your children, their No 2. Present participation in Youth Center activities by your chil ages, and which programs. List below: No Have you ever been convicted of a felony:If yes, please explain in detail: Do you currently have a violation(s) of City of Miami Beach code No If yes, please explain in detail: Do you currently owe the City of Miami Beach any money:No If yes, please explain in detail: Yes Are you currently serving on any City Boards or Committees:If yes, which board? Health Advisory What organizations in the City of Miami Beach do you currently h List all properties owned or have an interest in, which are loca I am now employed by the city of Miami Beach:No Which department? The following information is voluntary and is neither part of yo being asked to comply with federal equal opportunity reporting r Gender:Male Race/Ethnic Categories What is your race? Mark one or more races to indicate what you consider yourself t White Other Description: Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spani No No Physically Challenged: NOTEIf appointed, you will be required to follow certain laws which : These laws include, but are not limited to, the following: Prohibition from directly or indirectly lobbying city personnel o Prohibition from contracting with the city (Miami-Dade County Co o Prohibition from lobbying before board/committee you have served o Beach Code section 2-26). Requirement to disclose certain financial interests and gifts (M o (re: CMB Community Development Advisory Committee): prohibiti from having any interest in or receiving any benefit from Co or those with whom you have business or immediate family ties Upon request, copies of these laws may be obtained from the I hereby attest to the accuracy and truthfulness of the applica VII of the City Code Standards of Conduct for City Officers, I Anthony Japour agreed to the following terms on 12/30/2014 9:2 Received in the City Clerk's Office by: Name of Deputy Clerk Control No.Date Anthony J. Japour, M.D. Curriculum Vitae Anthony Japour & Associates, Medical and Scientific Consulting, 200 Ocean Drive, #5A Miami Beach, FL 33139 Tel: 305.989.4500 Email: ajjapour@me.com Japour_CV_AUG-2014 P. 1 TABLE OF CONTENTS FOR CURRICULUM VITAE No Subject Page No 1 EDUCATION 3 2 FULL-TIME ACADEMIC EXPERIENCE 3 3 PART-TIME ACADEMIC EXPERIENCE 3 4 NON-ACADEMIC EXPERIENCE 4 5 EMPLOYMENT RECORDS AT FIU 5 6 PUBLICATIONS IN DISCIPLINE 5 Invited Papers in Professional Journals 5 Peer Reviewed Research Articles 5 Book Chapters 8 8 Abstracts 16 Other Publications/Books 7 PRESENTED LECTURES AND PAPERS 16 Invited Lectures 16 Oral Presentations at Conferences 18 Poster Presentations at Conferences by Fellows 18 8 FUNDED RESEARCH 19 External Funding as PI 19 External Funding as Co-PI/Co-Investigator 19 Students/Fellows Funding/Fellowships 19 9 PROFESSIONAL HONORS, PRIZES AND FELLOWSHIPS 20 Local 20 National 20 TEACHING 10 20 List of courses taught at FIU 20 MENTORING (SCHOLARS & STUDENTS) 11 20 Medical Residents 20 Postdoctoral Fellows 20 12 OTHER PROFESSIONAL ACTIVITIES AND PUBLIC SERVICE 22 Editorial Boards 22 Journal Reviews 22 Grant Reviews 22 Conference Committees 22 Conference Committees-AIDS Clinical Trials Group (ACTG) 23 Others 23 University Service 23 Japour_CV_AUG-2014 P. 2 1. EDUCATION Degree Institution Field Dates University of Chicago Graduate School of Executive Training 2001 Business, Chicago IL Program, Finance Harvard Medical School Combined Infectious Post-Doctoral 1989-1992 Diseases Program (Beth Israel Hospital, Fellowship in Brigham & WomenÈs Hospital, Dana Farber Infectious Diseases Cancer Institute, Boston ChildrenÈs Hospital), Boston, MA Mount Auburn Hospital, Cambridge, MA Residency in Internal 1987-1989 Medicine Mount Auburn Hospital, Cambridge, MA Internship in Internal 1986-1987 Medicine th QueenÈs Square 4 Year Elective 1986 London, England Clerkship in Neurology Northwestern University Medical School, MD Medicine 1983-1986 Chicago, IL Harvard School of Dental Medicine, Basic Sciences 1981-1982 Boston MA University of Michigan, Ann Arbor, MI Liberal Arts BS 1977-1981 2. FULL-TIME ACADEMIC EXPERIENCE Institution Rank Field Dates Harvard Medical School, Boston, MA Assistant Internal Medicine/Infectious 1995-1996 Professor Diseases Harvard Medical School, Boston, MA Instructor Internal Medicine/Infectious 1992-1995 Diseases 3. PART-TIME ACADEMIC EXPERIENCE Institution Rank Field Dates Jackson North Medical Center Consultant Hepatitis, 2011-12 Jackson Health System, Miami FL HIV, Florida International University, Miami, FL Infectious Diseases Molecular Microbiology & Infectious Diseases, Associate Professor Infectious 2009- Herbert Wertheim College of Medicine Diseases 2013 Florida International University, Miami, FL VeteranÈs Administration Hospital, Without Infectious 2006- Miami, FL Compensation Disease 2012 Consultant University of Miami, Miami, FL. Voluntary Internal 2004- Medicine 2010 Associate Professor Japour_CV_AUG-2014 P. 3 Center for Medical Ethics, University of Chicago, Visiting Senior Medical 2002- Chicago, IL Fellow Ethics 2003 Medicine, Harvard Medical School, Visiting Lecturer Infectious 2002- Boston, MA Diseases 2003 Rush-Presbyterian St. LukesÈ Medical School, Assistant Internal 2002- Chicago, IL Medicine 2003 Professor Harvard Medical School, Boston, MA Assistant Internal 1996- Medicine 2001 Clinical Professor 4. NON-ACADEMIC EXPERIENCE Place of Employment Title Dates Elite Health Medical Group Health & Wellness Physician 2012-Present Miami Beach, FL Director, Hepatitis C Program Mount Sinai Medical Center Staff Physician 2012-Present Miami Beach, FL Anthony Japour & Associates, Managing Director 2006-Present Medical and Scientific Consulting, Inc., Miami Beach, Fl Research Physicians Network Alliance Principal Investigator 2012-2013 Miami Beach, FL Consultant Anthony Japour Medical and Scientific 2002-2006 Consultant, Miami Beach, Fl Abbott Laboratories, Global Medical Global Director 2001-2002 Affairs, Abbott Park, Il HIV & Immunology Franchises Marketed Product Development, Global Medical Affairs Abbott Laboratories, Abbott Park, Il Professional Development Director 2001-2002 Physician Rotation Program/ CME Course Director, Global Medical Affairs Abbott Laboratories, Abbott Park, Il Medical Director 1999-2001 HIV/Transplant Franchise, Medical Affairs Abbott Laboratories, Abbott Park, Il Associate Medical Director II 1998-1999 Antiviral Venture, Pharmaceutical Products Division Abbott Laboratories, Abbott Park, Il Associate Medical Director I 1996-1998 Antiviral Venture, Pharmaceutical Products Division Beth Israel Deaconess Medical Center, Senior Associate Physician 1995-1996 Boston, Ma Japour_CV_AUG-2014 P. 4 Beth Israel Deaconess Medical Center, Associate Physician 1992-1994 Boston, Ma 5. EMPLOYMENT RECORD AT FIU Rank Dates Associate Professor 2009-2013 6. PUBLICATIONS IN DISCIPLINE No Year Authors, Title, Journal Invited Papers in Professional Journals J. Feinberg, A. Japour. Scientific and Ethical Considerations in Trial Design for 5 2003 Investigational Agents for the Treatment of Human Immunodeficien Clinical Infectious Diseases 36: 1-6. 1995 Japour, A.J. The Clinical Significance of HIV-1 Drug Resistance and the Impact on 4 HIV Pathogenesis. AIDS Clinical Care 7(9). 1993 Collier, A., Henry, K., Japour, A.J., van der Horst, C. Switching and Combining 3 Antiretroviral Therapies - a Roundtable Discussion. AIDS Clinical Care 5:33-42. 1991 Japour, A.J. and Crumpacker, C.S. Zidovudine Resistance in HIV. AIDS Clinical Care 2 3:65-67. 1987 Japour, A.J. But First, A Little Chi Chi. Massachusetts Medicine. 1 Peer Reviewed Research Articles S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Rua 31 2002 Johnson, R. LaLonde, A. Japour, S. Brun, E. Sun. Lopinavir-Ritonavir Versus Nelfinavir for Initial Treatment of HIV Infection. New England Journal of Medicine 346:2039-2046. Benson, C.A., Deeks, S.G., Brun, S.C., Gulick, R.M., Eron, J.J., 30 2002 R.L., Hicks, C., King, M., Wheeler, D., Feinberg, J., Stryker, R Thompson, M., Real, K., Hsu, A., Kempf, D., Japour, A.J., Sun, E. Safety and Antiviral at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus 1-Infected Protease Inhibitor-Experienced. The Journal of Infectious Diseases 185:599-607. Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Xu, Y., Rea 29 2001 Japour, A.J., Sun, E., Rode, R.A. Identification of Genotypic Changes in Hum Immunodeficiency Virus Protease that Correlate with Reduced Susc Protease Inhibitor Lopinavir among Viral Isolates from Protease -Experienced Patients. Journal of Virology 75: 7462-7469. Murphy, R.L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King 28 2001 Benson, C., Thompson, M., Kessler, H.A., Hammer, S., Bertz, R., Japour, A., Sun, E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-nave adults with HIV-1 infection: 48-week results. AIDS 15:1-9. Gisolf, E.H., Jurriaans, S., Pelgrom, J., van Wanzeele, F., van 27 2000 Brinkman, K., Borst, M.J, de Wolf, F., Japour, A.J., Danner, S.A. The Effect of Treatment Intensification in HIV-Infection: A Study Comparing Treatment with Japour_CV_AUG-2014 P. 5 Ritonavir/Saquinavir and Ritonavir/Saquinavir/Stavudine. AIDS 14:405-413. Welles, S.L., Pitt, J., Colgrove, R., McIntosh, K., Chung, P.H.,kman, S., 26 2000 Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C., Z Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant Transmission In the Women and Infant Transmission Study. AIDS 14:263-272. Colgrove, R., Japour, A. A Combinatorial Ledge: Reverse Transcriptase Fidelity, Total 25 1999 Body Viral Burden, and the Implications of Multiple-Drug HIV Therapy For the Evolution of Antiviral Resistance. Antiviral Res 41:45-56. Cameron, D.W., Japour, A.J., XU, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., 24 1999 Poretz, D., Markowitz, M., Follansbee, S., Angel, J.B., McMahon, Devanarayan,V., Rode, R., Salgo, M.P., Kempf, D.J., Granneman, R and Sun, E. Ritonavir and Saquinavir Combination Therapy for the Treatment of HIV Infection. AIDS 13:213-224. Demeter, L.M., DÈAquila, R., Weislow, O., Lorenzo, E., Erice, A. 23 1998 Shafer, R., Richman, D., Howard, T.M., Zhao, Y., Fisher, E., Hua Sylvester, S., Arens, M., Sannerud, K., Rasheed, S., Johnson, V., Kuri Reichelderfer, P., Japour, A. Interlaboratory Concordance of DNA Sequence Analysis To Detect Reverse Transcriptase Mutations In HIV-1 Proviral DNA. J. Virol. Methods 75:93-104. Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L., Japour, A.J. Selective Vertical 22 1998 Transmission of HIV-1 Antiretroviral Resistance Mutations. AIDS 12:2281-2288. Hsu, A., Granneman, G.R., Cao, G., Carothers, L., Japour, A.J., El-Shourbagy, T., 21 1998 Dennis, S., Berg, J., Erdman, K., Leonard, J.M., Sun, E. Pharmac between Ritonavir and Indinavir in Healthy Volunteers. Antimicrob. Agents Chemo. 42: 2784-2791. Sham, H., Kempf, D., Molla, A., Marsh, K., Kumar, G., Chen, C., Kati, W., Stewart, K., 20 1998 Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Sudthida, V., M A., Wideburg, N., Chen, X., Niu, P., Park,nC., Jayanti, V., Grab R., Sun, E., Japour, A., Leonard, J., Plattner, J., Norbeck, D. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease. Antimicrob. Agents Chemo. 42:3218-3224. Fiscus, S.A., Hughes, M.D., Lathey, J.L., Pi, T., Jackson, B.J., 19 1998 Reichman, R., Japour, A.J., Byington, R., Scott, W., Griffith, B.P., Katzenstein, D.A., Hammer, S.M. Changes in Virologic Markers as Predictors of CD4 C Progression of Disease in Human Immunodeficiency Virus Type 1-Infected Adults Treated with Nucleosides. J. Infect. Dis. 177:625-633. Kew, Y., Olsen, L.R., Japour, A.J., Prasad, V.R. Insertions into the 3-4 Hairpin 18 1998 Loop of HIV-1 Reverse Transcriptase Reveal a Role for Fingers Subdomain in Processive Polymerization. J. Biol. Chem. 273:7529-7537. Lathey, J.L., Hughes, M.D., Fiscus, S.A., Pi, T., Jackson, J.B., Rasheed 17 1998 Reichman, R., Japour, A.J., DÈAquila, R.T., Scott, W., Griffith, B.P., Hammer, S.M., Katzenstein, D.A. Variability and Prognostic Values of Virologic Measures in Human Immunodeficiency Virus Type 1-Infected Patients with 200-500 3 CD4 Cells/mm (ACTG 175). J. Infect. Dis. 177:617-24. Kempf, D.J., Rode, R.A., Xu, Y., Sun, E., Heath-Chiozzi, M.E., Valdes, J., Japour, 16 1998 A.J., Danner, S., Boucher, C., Molla, A., Leonard, J.M. The Duration of Viral Suppression During Protease Inhibitor Therapy for HIV-1 Infection is Predicted by Plasma HIV-1 RNA at the Nadir. AIDS 12:F9-F14. Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory 15 1997 Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor Japour_CV_AUG-2014 P. 6 Patients with Advanced HIV-1 Disease. Lancet 351:252-255. Marschner, I.C., Mayers, D.L., Erice, A., Smeaton, L., Johnson, 14 1997 Reichelderfer, P., Japour, A.J. Standardized Peripheral Blood Mononuclear Cell Culture Assay for Zidovudine Susceptibility Testing of Clinical Immunodeficiency Virus Type 1 Isolates: Effect of Reducing the Replicates and Concentrations. J. Clin. Microbiol. 35:756-758. Katzenstein, D.A., Hammer, S.M., Hughes, M., Gundacker, H., Jack 13 1996 Rasheed, S., Elbeik, T., Reichman, R., Japour, A.J., Merigan, T.C., Hirsch, M. The Relation of Virologic and Immunologic Markers to Clinical Outcomleoside Therapy in HIV-Infected Adults With 200 to 500 CD4 Cells Per Cubic Millimeter. New England J. Med. 335:1091-1098. Shafer, R.W., Winters, M.A., Mayers, D., Japour, A.J., Kuritzkes, D., Weislow, O., 12 1996 White, F., Erice, A., Sannerud, K., Iversen, A., Pena, F., Dimitrov, D., Frenkel, S., Reichelderfer, P.S. Inter-Laboratory Comparison of Sequence-Specific PCR and Ligase Detection Reaction to Detect an HIV-1 Drug Resistance Mutation. J. Clin. Microbiol. 34:1849-1853. Coombs, R.W., Welles, S.L., Hooper, C., Reichelderfer, P.S., DÈAquila, R.T., Japour, 11 1996 A.J., Johnson, V.A., Kuritzkes, D.R., Richman, D.D., Kwok, S., Todd, DeGruttola, V., Crumpacker, C.S., and Kahn, J. Association of Pl Immunodeficiency Virus Type-1 RNA Level With Risk of Clinical Progression in Patients With Advanced Infection. J. Infect. Dis. 174:704-712. 10 1996 Japour, A.J., Lertora, J.J., Meehan, P.M., Erice, A., Connor, J.D., Griffith P.A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J., McLaren, C., Johanneson, N., Wood, K., Booth, D.K., Bassiakos, Y for the AIDS Clinical Trials Group 231 Protocol Team. A Phase I Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin. J. Acquired Immune Defic. Syndromes Hum. Retrovirol. 13:235-246. Japour, A.J., Welles, S., DÈAquila, R.T., Johnson, V.A., Richman, D.D., Coom 9 1995 R.W., Reichelderfer, P.S., Kahn, J., DeGruttola, V., Crumpacker,C.S., Kuritzkes, D.R. Prevalence and Clinical Significance of Zidovudine (ZDV) Resista Human Immunodeficiency Virus Isolated from Patients Following Lo-Term Zidovudine Treatment. J. Infect. Dis. 171:1172-1179. Welles, S., Jackson, J., Yen-Lieberman, B., Demeter, L., Japour, A.J., Smeaton, L.M., 8 1995 Johnson, V., Kuritzkes, D., D'Aquila, R., Reichelderfer, P., Ric Fischl, M., Dolin, R., Coombs, R., Kahn, McLaren, C., Todd, J., Crumpacker, C. Prognostic Value of Plasma HIV-1 RNA Levels in Patients with Advanced HIV-1 Disease and With Little or No Zidovudine Therapy. J. Infect. Dis. 174:696-703. D'Aquila, R.T., Johnson, V.A., Welles, S.L., Japour, A.J., Kuritzkes, D., DeGruttola, 7 1995 V., Reichelderfer, P.S., Coombs, R.W., Crumpacker, C., Kahn, J.O., Richman, D.D. Zidovudine Resistance and Human Immunodeficiency Virus Type 1 Di Progression During Antiretroviral Therapy. Annals Internal Med. 122:401-408. Lan, Y., Japour, A.J., Kim, S., Welles, S.L., Crumpacker, C.S., Cooper, E., Al-Attar, I., 6 1995 McIntosh, K. A Rapid, Direct Test for Zidovudine Susceptibility Human Immunodeficiency Virus Type 1 (HIV-1) From Infected Children. Clinic. Diag. Virol. 3:259-271. Mayers, D.L., Japour, A.J., Arduino, J.M., Hammer, S.M., Reichman, R., Wagner, 5 1994 K.F., Chung, R., Lane, J., Crumpacker, C.S., McLeod, G.X., Becke C.R., Winslow, D., Burke, D. and the RV43 Study Group. Dideoxynu Resistance Emerges with Prolonged Zidovudine Monotherapy. Antimicrob. Agents Japour_CV_AUG-2014 P. 7 Chemo. 38:307-314.. Japour, A.J., Fiscus, S.A., Arduino, J.M., Mayers, D.L., Reichelderfer, P.S. 4 1994 D.R. Standardized Microtiter Assay for Determination of Syncytiu-Inducing Phenotypes of Clinical Human Immunodeficiency Virus Type 1 Isolates. J. Clinic. Microbiol. 32:2291-2294. 3 1993 Japour, A.J., Mayers, D.L., Johnson, V.A., Kuritzkes, D.R., Beckett, L.A., A J.M., Lane, J., Black, R.J., Reichelderfer, P.S., D'Aquila, R.T.cker, C.S. The RV-43 Study Group, The AIDS Clinical Trials Group Virology Committe Working Group. A Standardized Peripheral Blood Mononuclear Cell the Determination of Drug Susceptiblities of Clinical Human Immurus-1 (HIV-1) Isolates. Antimicrob. Agents Chemo. 37:1095-1101. A.J. Japour, P.A. Chatis, H.A. Eigenrauch, C.S. Crumpacker. Detection of Hu 2 1991 Immunodeficiency Virus Type 1 Clinical Isolates With Reduced Sen Zidovudine and Dideoxyinosine by RNA-RNA Hybridization. PNAS 88:3092-3096. Keith, D.A., Gundberg, C.M., Japour, A.J., Arnoff, J., Alverez, N., Gallop, P.M. 1 1983 Vitamin K Dependent Proteins and Anticonvulsant Medications. Clinic. Pharm. Therap. 34:529-32. Book Chapters A.J. Japour. Informed Consent, Ethical Issues in Performing HIV Research. 4 2007 Fundamentals of HIV Medicine. American Association of HIV Medicine. Washington DC, 54.2:722-724. A.J. Japour. Ethical Conduct of Clinical Trials, IRBs, and Financial Conflict of 3 2007 Interest, Ethical Issues in Performing HIV Research. Fundamentals of HIV Medicine. American Association of HIV Medicine, Washington DC 54.1:717-721. A.J. Japour. Management of CMV Disease. In Cotton DJ & Watts DH (eds): Medical 2 1997 Management of AIDS in Women, New York: John Wiley & Sons, Inc. A. Molla, A.J. Japour. HIV Protease Inhibitors. Current Opinion in Infectious Diseases 1 1997 10:491-495. Abstracts 86 2009 Welles S., Lichtenberger P, Fertil J., Medina R., Cousino G., Ro, Japour A., Factors Associated with Antiretroviral Therapy Adherence (ART-AD) among HIV + Women in the Miami-Dade County Health Department AIDS Drug th Assistance Program (MDC-ADAP). American Public Health Association 137 Annual Meeting. Japour A 85 2007 Gagnon J., Welles S., . Factors affecting HIV therapy adherence amongst marginalized urban men who have sex with men (MSM). Ame th Public Health Association 135 Annual Meeting. 84 2006 Gulnik S., AfoninaE., Eissenstat M., Parkin N., JapourA., and Erickson J. SPI-256, a th Highly Potent HIV Protease Inhibitor with Broad Activity against Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, February 5-8. 83 2002 Cameron, D., Angel, J., Ryan, J., Jiang, P., Rode, R., Farthing, C., Cohen, C., Mellors, J., Poretz, D., Markowitz, M., Ho, D., McMahon, D., Drennan, D., Japour, A.J. Durability of Ritonavir (RTV) Saquinavir (SQV) Dual Protease I th Therapy in HIV infection: 5-Year Follow-up. 9 CROI February 24-28, Seattle, WA. 82 2002 Cohen, C., Shen, Y., Rode, R., Cameron, D., Mellors, J., Farthin Markowitz, M., Ho, D., McMahon, D., Drennan, D., Selness, K., Su Japour, A.J., Ryan, J. for the M96-462 Study Group Effect of Nucleoside (NRTI) Intensification on Prevalence of Morphologic Abnormalities (MoAs Japour_CV_AUG-2014 P. 8 th Ritonavir plus Saquinavir (SQV) Therapy in an HIV-Infected Cohort. 9 CROI February 24-28, Seattle, WA. 81 2002 Steinberg, S., Venuto, R., Kuruvila, K., Taylor, D., Anil Kumar, M., First, M., Greco, R., Boodhoo, T., Singh, A., Ashraf, T., Japour, A., Ryan, J. A Randomized, Open-label ¨¨ Preference Study of Gengraf Compared to Neoral in Stable Solid-organ Transplant th Recipients., 7 International Society of Pharmacoeconomics and Outcomes Research - ISPOR, Arlington, May 19-21. Published in Value in Health 6(3), 198-290. 80 2001 Harley, W., DeJesus, E., Pistole, M., Sension, M., Garrett, L., Rode, R., Ashraf, T., McMillan, F., Japour, A. A 24-Week Randomized, Controlled, Open-Label Evaluation of Adherence and Convenience of Continuing Indi th Switching to Ritonavir/Indinavir 400 mg/400 mg BID (The NICE Stu Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 4-8. 79 2002 Hsu, A., Zolopa, A., Shulman, N., Havlir, D., Gallant, J., Race, Swerdlow, J., Jasinsky, O., Renz, C., Japour, A., Kempf, D., Sun, E. Final Analysis of Ritonavir (RTV) Intensification in Indinavir (IDV) Recipients with Detectable HIV th RNA Levels. 8 Conference on Retroviruses and Opportunistic Infections, Chicag Illinois, February 4-8. 78 2001 Cohen, C., Ryan, J., Jiang, P., Cameron, D.W., Mellors, J., Kaku Japour, A.J. Effect of Nucleoside Intensification on Prevalence of Morphologic A st Year 4 of Ritonavir + Saquinavir Therapy in an HIV-Infected Cohort. 1 IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7. 77 2001 Farthing, C., Ryan, J., Rode, R., Markowitz, M., Cameron, D.W., McMahon, D., Japour, A.J. Durability of Ritonavir + Saquinavir Dual Protease Inhibitor T st HIV Infection: Four-Year Follow-Up. 1 IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7. 76 2001 King, M., Brun, S., Marsh, T., Real, K., Kempf, D., Japour, A., Sun, E. Factors Affecting Long-Term Virologic Suppression in Phase II Studies of Lopinavir/rito st (LPV/r) in ARV-Nave or PI-Experienced Patients. 1 IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7. 75 2001 Sension, M., Harley, W., DeJesus, E., Jiang, P., Garrett, L., Mc Japour, A. Final Analysis of a 24-Week Randomized, Controlled, Open-Label Evaluation of Adherence and Convenience of Continuing Indinavir vs. Switching to st Ritonavir/Indinavir 400 mg/400 mg BID. 1 IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7. 74 2001 Hicks, C., Brun, S., King, M., Marsh, T., Deeks, S., Benson, C., Murphy, R., Wheeler, D., Feinberg, J., Eron, J., Sax, P., Stryker, R., Ri Thompson, M., Richards, B., Kempf, D., Japour, A., Sun, E. for the M97-765 Study. Kaletra (Lopinavir/Ritonavir) Therapy in Single Protease Inhibit th Patients: 144 Week Follow Up. 8 European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, October 28-31. 73 2001 Perrin, L., King, M., Brun, S., Yerly, S., Marsh, T., Travers, N Japour, A., Sun, E. Failure to Achieve HIV RNA < 3 Copies/mL Does Not Predict Loss of st Virologic Response to Kaletra (Lopinavir/Ritonavir) Therapy through 3 Years. 41 Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19. 72 2001 Piliero, P.J., Preston, S.L., Japour, A.J., Stevens, R.C., Morvillo, C., Drusano, G.L. Pharmacokinetics (Pk) of the Combination of Ritonavir (RTV) Plus st with and without Efavirenz (EFV), in Health Volunteers. 41 Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19. 71 2000 Coplan, P., Cormier, K., Japour, A., Mardit-Kremers, H., Nikas, A., Lewis, R., Xu, Y. Japour_CV_AUG-2014 P. 9 th Myocardial Infarction Incidence in Clinical Trail of 4 Protease Inhibitors. 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 70 2000 Gulick, R., King, M., Brun, S., Real, K., Murphy, R., Hick, C., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler, H., Kempf, D., Sun, E., Japour, A. ABT-378/Ritonavir (ABT-378/r) in Antiretroviral- th Nave HI+ Patients 72 Weeks. 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 69 2000 Gisolf, E. H., Jurriaans, S., Pelgrom, J., Van Wanzeele, F., Van Brinkman, K., Borst, M. J., De Wolf, F., Sun, E., Japour, A., Danner, S. A. Ritonavir/Saquinavir Versus Ritonavir/Saquinavir/Stavudine in HI-1-Infected th Individuals During 48 Weeks: The Effect of treatment Intensifica Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 68 2000 Deeks, S., Brun, S., XU, Y., Real, K., Benson, C., Kessler, H., Hicks, C., Eron, E., Feinberg, J., Gulick, R., Sax, P., Stryker, M., King, M., Potthoff, A., Hsu, A., Bertz, R., Molla, A., Mo, H., Kempf, D., Japour, A., Sun, E. ABT-378/Ritonavir (ABT-378/r) Suppresses HIV RNA to <400 Copies/ml th in 84% of PI-Experienced Patients at 48 Weeks. 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 67 2000 Cameron, D.W., Xu, Y., Rode, R., Cohen, C., Mellors, J., Farthin Markowitz, M., Ho, D., McMahon, D., Drennan, D., Hill, L., Sun, Japour, A. Three- Year Follow-Up and Conditional Outcomes Survival Analysis of Ritonavir (RTV) th Saquinavir (SQV) Therapy in HIV Infection. 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 66 2000 Shulman, N., Zolopa, A., Havlir, D., Gallant, J., Race, E., Lam,Japour, A., Kempf, D., Sun, E., Hsu, A. Ritonavir Intensification in Indinavir Recipients with th Detectable HIV RNA Levels. 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 65 2000 Pitt, J., Colgrove, R., Thompson, B., Japour, A., Welles, S. Association of Maternal ZDV Use during Pregnancy and Infant ZDV Genotypic Resistance with Rap th Progression among Infants in the WITS. 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 64 2000 Kempf, D., Xu, Y., Brun, S., King, M., Mo, H., Real, K., Bernstein, B., Hertogs, K., Larder, B., Molla, A., Japour, A., Sun, E. Baseline Genotype Phenotype Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks. th 7 Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2. 63 2000 Molla, A., Brun, S., Mo, H., Real, K., Poddig, J., Bernstein, B. Lie, Y., Hellmann, N., Vasavanonda, S., Chernyavskiy, T., Freimu Japour, A., Sun, E., Kempf, D. Genotypic and Phenotypic Analysis of Viral Isolates from Subjects th with Detectable Viral Load on Therapy With ABT-378/Ritonavir (ABT-378/r). 4 International Workshop on HIV Drug Resistance Focuses on New Ant-HIV Drugs Sitges, Portugal, June 12-16. 62 2000 Kempf, D., Isaacson, J., King, M., Brun, S., Xu, Y., Real, K., Lie, Y., Hellmann, N., Hertogs, K., Larder, B., Bernstein, B., Japour, A., Sun, E., Rode, R. Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients th Failing Protease Inhibitor Therapy. 4 International Workshop on HIV Drug Resistance Focuses on New Anti-HIV Drugs, Sitges, Portugal, June 12-16. 61 2000 Kessler, H., Brun, S., King, M., Marsh, T., Murphy, R., Eron, J. Hicks, C., Benson, C., Thompson, M., Thommes, J., Deeks, S., Wheeler, D., White, C., Stryker, R., Feinberg, J., Albrecht, A., Sax, P., Riddler, S., R Japour, A., Sun, E. Analysis of Safety Data from ABT-378/ritonavir (ABT-378/r) in Two Phase II Japour_CV_AUG-2014 P. 10 Clinical Trials XIII International AIDS Conference, July 9-14. 60 2000 Thompson, M., Brun, S., Xu, X., Murphy, R., Eron, J., Gulick, R. C., Benson, C., Thommes, J., Kessler, H., Deeks, S., Wheeler, D. Feinberg, J., Albrecht, M., Sax, P., Riddler, S., Real, K., King, M., Japour, A., Sun, E., Analysis of Duration of Virologic Response in Two Phase II Studi- 378/ritonavir (ABT-378/r) at 72 Weeks. XIII International AIDS Conference, July 9-14. 59 2000 Thompson, M., Murphy, R., Gulick, R., Hicks, C., Eron, J., Benson, C., Thommes, J., Kessler, H., Deeks, S., Wheeler, D., White, C., Stryker, R., Fei Sax, P., Riddler, S., Real, K., King, M., Japour, A., Sun, E., Analysis of Duration of Virologic Response in Two Phase II Studies of ABT-378/ritonavir (ABT-378/r) at 72 Weeks. XIII International AIDS Conference, July 9-14. 58 2000 DeJesus, E., Pistole, M., Fetchick, R., Lauermann, M., Roland, R McMillan, F., Japour, A. A Randomized, Controlled, Open-Label Study Comparing the Adherence and Convenience of Continuing Indinavir Q8H vs. Switch Norvir/Indinavir 400 mg/400 mg BID (The NICE Study). XIII International AIDS Conference, July 9-14. 57 2000 Hsu, A., Williams, L., Chiu, Y-L., Hill, L., McMillan, F., Lamm, J., Rynkiewicz, K., Foit, C., Ji, Q., Hutman, W., Ryan, J., Sun, E., Japour, A. Pharmacokinetic (PK) Interactions Between Ritonavir (RTV) and Amprenavir (APV) in Hea XIII International AIDS Conference, July 9-14. 56 2000 Havlir, D., Gallant, J., Race, E., Lam, W., Schulman, N., Zolopa,Japour, A., Kempf, D., Sun, E. Ritonavir Intensification in Indinavir Recipients: Tolerance, Antiviral Effect and Pharmacokinetics. XIII International AIDS Conference, July 9-14. 55 2000 Williams, L., OÈDea, R., Weinberg, M., Keene, M., Japour, A., Centko, M., Bachand, J., Hsu, A., Hill, L., Lamm, J. High Incidence of Rash Associated with Amprenavir (APV) During a Pharmacokinetic (PK) Interaction Trial in HIV-Negative, Healthy Volunteer. XIII International AIDS Conference, July 9-14. 54 2000 Benson, C., King, M., Marsh, T., Murphy, R., Hicks, C., Thommes, Thompson, M., White, C., Albrecht, M., Kessler, H., Hsu, A., Ber Travers, N., Real, K., Japour, A., Sun, E. ABT-378/ritonavir (ABT-378/r) in th Antiretroviral-nave HIV+ Patients: 96 Weeks. 40 ICAAC Conference, Toronto, Canada, September 17-20. 53 2000 Brun, S., Kempf, D., Molla, A., Mo, H., Xu, Y., Real, K., Poddig Larder, B., Freimuth, W., Japour, A., Sun, E. Analysis of Viral Isolates Following Viral th Load Rebound on Therapy with ABT-378/ritonavir (ABT-378/r). 40 ICAAC Conference, Toronto, Canada, September 17-20. 52 2000 Feinberg, J., Brun, S., Marsh, T., Benson, C., Deeks, S., Kessler, H., Murphy, R., Gulick, R., Wheeler, D., Hicks, C., Eron, J., Sax, P., Stryker, M., Real, K., Hsu, A., Bertz, R., Kempf, D., Japour, A., Sun, E. Durable Suppression of HIV+ RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in Single Protease th Inhibitor Experienced Patients. 40 ICAAC Conference, Toronto, Canada, September 17-20. 51 2000 Stryker, R., Brun, S., King, M., Marsh, T., Murphy, R., Hicks, C Gulick, R., Glesby, M., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler, H., Real, K., Japour, A., Perrin, L., Sun, E. Kaletra (ABT-378/ritonavir) in Anti- retroviral-Nave HIV+ Patients: Follow-up Beyond Two Years and Viral Load th Suspension Below 3 Copies/mL. 40 ICAAC Conference, Toronto, Canada, September 17-20. 50 2000 Benson, C., Brun, S., King, M., Real, K., Murphy, R., Hicks, C., Gulick, R., Glesby, M., Thompson, M., White, C., Albrecht, M., K Japour_CV_AUG-2014 P. 11 Sun, E., Japour, A. Two Year Follow-Up of ABT-378/Ritonavir (ABT-378 in th Antiretroviral Nave HIV + Patients. 40 ICAAC Conference, Toronto, Canada, September 17-20. 49 2000 Bertz, R., Lam, W., Rynkiewicz, C., Foit, I., Benedek, W., Fiske Brun, S., Japour, A., Granneman, G.R., Sun, E. Assessment of the Pharmacokinetic Interaction Between ABT-378/ritonavir (ABT-378/r) and Efavirenz (EFV) in Healthy th Volunteers and in HIV + Subjects. 40 ICAAC Conference, Toronto, Canada, September 17-20. 48 2000 Feinberg, J., Brun, S. Marsh, T., King, M., Benson, C., Deeks, S., Kessler, H. R., Gulick, R., Wheeler, D., Hicks, C., Eron, J., Sax, P., Stryk Thompson, M., Real, K., Hsu, A., Bertz, R., Kempf, D., Japour, A., Sun, E. Durable suppression of HIV + RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in th Single Protease Inhibitor Experienced Patients. 5 International Congress on Drug Therapy in HIV Infection, Glasgow, UK, October 22-26. 47 2000 Stryker, R., Brun, S., King, M., Marsh, T., Murphy, R., Hicks, C., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Benson, C., Alb H., Real, K., Japour, A., Perrin, L., Sun, E. Kaletra (ABT-378/ritonavir) in Antiretroviral-Nave HIV + Patients: Follow-up Beyond Two Years and Viral Load th Suppression Below 3 Copies/mL. 5 International Congress on Drug Therapy in HIV Infection, Glasgow, UK, October 22-26. 46 2000 Cohen, C., Cameron, D., Xu, Y., Rode, R., Mellors, J., Farthing, Markowitz, D., Ho, D., McMahon, D., Drennan, D., Selness, K., Ry J., Sun, E., Japour, A.J. Effect of NRTI Intensification on Prevalence of Body Composition Abnormalities at Week 144 of Ritonavir + Saquinavir Therapy in an HIV-Infected nd Cohort. 2 International Workshop on Adverse Drug Reactions and Lipdystrop HIV Toronto, CA, September 13-15. 45 1999 Murphy, R., King, M., Brun, S., Orth, K., Hicks, C., Eron, J., T Thompson, M., White, C., Benson, C., Hammer, S., Kessler, H., Bertz, R., Hsu, A., Kempf, D., Sun, E., Japour, A. ABT-378/ritonavir Therapy in Antiretroviral-Nave th HIV-I Infected Patients for 24 weeks. 6 Conference on Retroviruses and Opportunistic Infections, January 31 - February 4. 44 1999 Mo, H., Chernyavskiy, T., Lu, L., Staser, J., Cohen, C., Cameron, W., M Xu, Y., Kohlbrenner, W., Sun, E., Kempf, D., Japour, A., Molla, A. Characterization of th HIV-1 in Patients Following Long Term RTV-SQV Therapy. 6 Conference on Retroviruses and Opportunistic Infections, January 31 - February 4. 43 1999 Colgrove, R., Pitt, J., Japour, A., Welles, S. Evolutionary Hotspot Around RT Codon th 215 Evolves During Zidovudine Exposure. 6 Conference on Retroviruses and Opportunistic Infections, January 31 - February 4. 42 1999 Hsu, A., Granneman, R., Xu, Y., Rode, R., Japour, A., Leonard, J., Sun, E. Initial HIV Clearance Rates Do Not Predict Long-Term Antiviral Activity for Ritonavir-Saquinavir th (R-S) Combination Therapy in HIV-Protease Inhibitor-Nave Patient. 6 Conference on Retroviruses and Opportunistic Infections, January 31 Ã February 4. 41 1999 Bertz, R., Lam, W., Brun, S., Kumar, G., Fields, C., Orth, K., J Granneman, R., Japour, A., Sun, E. Multiple-Dose Pharmacokinetics (PK) of ABT- th 378/Ritonavir (ABT-378/r) in HIV+ Subjects. 39 ICAAC Conference on Antimicrobial Agents and Chemotherapy, September 26-29. 40 1999 Hsu, A., Lal, R., Bertz, R., Lam, W., Jennings, J., Brooks, R., Sun, E., Japour, A. ABT-378 and Ritonavir Exposures Are Not Predicted by th Erythromycin Breath Test (ERMBT). 39 ICAAC Conference on Antimicrobial Agents and Chemotherapy, September 26-29. Japour_CV_AUG-2014 P. 12 39 1999 Hicks, C., King, M., Brun, S., Real, K., Murphy, R., Eron, J., T R., Glesby, M., Thompson, M., White, C., Benson, M., Albrecht, M., K Bertz, R., Kempf, D., Japour, A., & Sun, E. ABT-378/Ritonavir (ABT-378/R) in Antiretroviral Nave HIV + Patients: 48 Weeks. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 23-27. 38 1999 Lal, R., Bertz, R., Lam, W., Jennings, J., Brooks, R., Bryan, P. G.R., & Japour, A. Evaluation of the Pharmacokinetics (PK) of the Concurrent Administration of ABT-378/Ritonavir (ABT-378/R) and Nevirapine (NVP). 7th European Conference on Clinical Aspects and Treatment of HIV Inf Portugal, October 23-27. 37 1998 Lal, R., Hsu, A., Granneman, G.R., El-Shourbagy, T., Johnson, M., Lam, W., Manning, L., Japour, A.J., Sun, E. Abbott Laboratories, Illinois ÅMultiple Dose Safety, Tolerability and Pharmacokinetics of ABT-378 in Combination with Ritonavir.Æ 5th Conference on Retroviruses and Opportunistic Infections. Chicag. 36 1998 Colgrove, R., Pitt, J., Chung, P., Welles, S., Japour, A.J., Harvard Medical School, Boston, Massachusetts, Columbia University, and University of Mi Minneapolis, Minnesota. Selective Vertical Transmission of HIV-1 Zidovudine th Resistance Mutations. 5 Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. 35 1998 Mellors, J., Japour, A.J., Cameron, W., Cohen, C., Farthing, C., Follansbee, S., Markowitz, M., Poretz, D., Ho, D., McMahon, D., Xu, Y., Rode, R. Berg, J., Salgo, M., Leonard, J., Sun, E. Sustained Activity of Ritonavir (RTV) th Saquinavir (SQV) in Protease Inhibitor-Nave Patients After 72 Weeks. 5 Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. 34 1998 Cameron, D.W., Japour, A.J., Mellors, C., Farthing, C., Cohen, C., Markowitz, M., Poretz, D., Follansbee, D., Ho, D., McMahon, D., Berg, J., Nieve Salgo, M., Leonard, J., Sun, E. Antiretroviral Safety & Durabili- th Saquinavir (SQV) in Protease Inhibitor-Nave Patients in Year Two of Follow-up. 5 Conference on Retroviruses and Opportunistic Infections, Chicago. 33 1998 Japour, A.J., Kempf, D., Mo, H., Chernyavskiy, T., Kohlbrenner, W., Sun, E., A. HIV Protease Mutations Following Ritonavir-Saquinavir Therapy and Long-Term nd Outcome on Plasma Viral Load Following an Intensification Strate International Workshop on HIV Drug Resistance and Treatment Strategies, Lake M June 24-27. 32 1998 Hsu, A., Granneman, R., Molla, A., Vasavanonda, S., Japour, A., Kempf, D., Sun, E. Ritonavir-Containing Dual Protease Inhibitor Regimens May Have Synergistic th Effects in Patients - Base on In Vitro Model. 12 World AIDS Conference, Geneva, Switzerland, June 28 - July 3. 31 1998 Mellors, J., Japour, A., Leonard, J., Sun, E., Xu, Y., Salgo, M., M97-462 Study Groups. Ritonavir (RTV)-Saquinavir (SQV) in Protease Inhibitor-Nave Patients after 72 Weeks. th 12 World AIDS Conference, Geneva, Switzerland, June 28 - July 3. 30 1998 Gisolf, E.H., De Wolf, F., Pelgrom, J., Van Wanzeele, F., Popesc Japour, A., Danner, S.A., Van Leeuwen, R. Treatment of Ritonavir (RTV)/Saqui th Versus RTV/SQV/Stavudine (d4T) (The Prometheus Study): Prelimina Results. 12 World AIDS Conference, Geneva, Switzerland, June 28 - July 3. 29 1997 Race, E., Adelson-Mitty, J., Barlam, T., and Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease I th Patients with Advanced HIV-1 Disease. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 352. 28 1997 Colgrove, R., Japour, A.J. Mathematical Modeling of Within-Patient Evolution of Japour_CV_AUG-2014 P. 13 HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcriptase Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority of Three- th drug Over Two-drug Therapeutic Regimens. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 406. 27 1997 Race, E., Reimann, K., Letvin, N. and Japour, A.J. Recurrence of Trimethoprim- Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease th Inhibitor (PRI) in Patients with Advanced HIV-1. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 535. 26 1997 Sun, E., Xu, Y., Hsu, A., Japour, A.J., Korneyeva, M., Molla, A., Kempf, D., Leonard, J., and The Ritonavir-Saquinavir Study Group. Predictability of Response to Ritonavir- Saquinavir (RTV-SQV) Combination Therapy. Keystone, April. 25 1997 Molla, A., Korneyeva, M., Chernyavskiy, T., Colgrove, R., Chung,Japour, A.J., Mellors, J., Xu, Y., Rode, R., Hsu, A., Granneman, G., Kempf, D.. and M96-462 Study Team. Characterization of HIV-1 Protease (PR) Mutations, Compliance, and Drug Concentrations in Patients Who Have an HIV RNA Rebo Ritonavir-Saquinavir (RTV-SQV). International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, 8-28. 24 1997 Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Colson, A., Lockman, Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Ri Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, California, September. 23 1997 Lal, R., Hsu, A., Chen, P., Dennis, S., El Shourbagy, T., Locke,Japour, A.J., Leonard, J., Granneman, G.R., Sun, E. Single Dose Pharmacokinetics of ABT-378 th in Combination with Ritonavir. 37 ICAAC. September 28-October 1. 22 1997 Gisolf, E., Colebunders, R., Van Wanzeele, F., Van Der Ende, M., Portegies, P., Hoetelmans, R., Japour, A.J., Ward, P., De Wolf, F., Danner, S., on behalf of the Prometheus Study Group. Treatment with Ritonavir/Saquinavir Versus Ritonavir/Saquinavir/Stavudine. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany, 354, October. 21 1995 Japour, A.J., Lertora, J., Meehan, P., Clax, P., Connor, J., Pollard, R., McL Johannesson, N., Erice, A., Cooney, E., Holden-Wiltse, J., Hussey, S., Walesky, M., Wood, K., Booth, D., Purdue, L., Greenspan, D., Kasdan, P., Basi Pettinelli, C. and Crumpacker, C. A Phase I Study of the Safety, Toleranc Pharmacokinetics of Combination Didanosine/Ribavirin for HIV Dis 2nd National Conference on Human Retroviruses, Washington, D.C.102. 20 1995 Welles, S., Jackson, J., Yen-Lieberman, B., Demeter, L., Japour, A., Johnson, V., Kuritzkes, D., D'Aquila, R., Reichelderfer, P., Richman, D., Rei Todd, J., Kwok, S., Fischl, M., Dolin, R. and Crumpacker, C. Prognostic Capacity of Plasma HIV-1 RNA Copy Number in ACTG 116A. 2nd National Conference on Human Retroviruses, Washington, D.C. 96. 19 1995 Japour, A.J., Drosopoulos, W., Katapodis, N., Chung, P.H., Kew, Y., Prasad, V. Saturation Mutagenesis of the HIV-1 RT b3- b4 Hairpin Reveals Novel Mutations Conferring Dideoxynucleoside Triphosphate Resistance. Fourth Workshop on Viral Resistance, Annapolis, Maryland. R 18 1995 Japour, A.J. & Pitt, J. Maternal-Infant Transmission of Zidovudine-Resistant (ZDV) HIV-1. Infectious Diseases Society of America Meetings, San Francisco, California. 17 1995 Japour, A.J., Kim, S., Greene, R., Joseph, R., Chatis, P. Clinical HIV-1 Isolates th Displaying ddI-Resistance in Culture May be Unstable With Serial Passage. 35 Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Japour_CV_AUG-2014 P. 14 California, I280. 16 1995 Chatis, P.A., Brewster, F., Joseph, R.A., Greene, R.A., Japour, A.J. A Direct Method th for Detection of Nevirapine Resistance in HIV-1 Clinical Isolates. 35 Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, I281. 15 1995 Demeter, L., Sannerud, K., Mayers, D., Fitzgibbon, J., Sylvester E., Shafer, R., Zhao, Y., Huang, D., Reichelderfer, P., Johnson, Rasheed, D., Kuritzkes, D., and Japour, A.J., for the ACTG Genotypic Resistance Working Group. Interlaboratory Concordance of DNA Sequence Analysis of the HIV-1 th Reverse Transcriptase. 35 Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, I284. 14 1995 Erice, A., Brambilla, D., Demeter, L., Penas, J., Brewster, F., Reichelderfer, P., Mayers, D., and Japour, A.J., for the ACTG Virology Committee. th Zidovudine (ZDV) Susceptibility Screening Assay for Clinical HIV Isolates. 35 Interscience Conference on Antimicrobial Agents and Chemotherapy California, I285. 13 1994 Greene, R.A., Japour, A., Joseph, R., Kasila, P., Litt, G., Chatis, P. A Direct Method f Detection of ddI Resistance in HIV-1 Clinical Isolates. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October. 12 1993 Japour, A.J., Chatis, P., Kim, S., Crumpacker, C.S. HIV-1 DDI-Resistance Overcome With Combination DDI/Ribavirin. IX International Conference on AIDS, Berlin, Germany, Abstract #PoA26-0640, June. 11 1993 Japour, A.J., Fiscus, S., Mayers, D., Reichelderfer, P., Kuritzkes, D. Micr Modification of the MT-2 Syncytia Assay. IX International Conference on AIDS, Berlin, Germany, PoB41-2484, June. 10 1993 D'Aquila, R., Johnson, V., Kuritzkes, D., Japour, A.J., Crumpacker, C., Richman, D. HIV-1 Drug Resistance and Syncytium-Inducing Phenotype: Associations With Disease Progression Among ACTG 116B/117 Subjects. IX International Confe Berlin, Germany, PoB26-2046, June. 9 1993 Lan, Y., Japour, A.J., Kim, S., Crumpacker, C.S., Welles, S.L., McIntosh, K. A Rapid, Direct Test for Zidovudine Susceptibility in Clinical Isolates o Immunodeficiency Virus Type 1 (HIV-1) From Infected Children. IX International Conference on AIDS, Berlin, Germany, PoB262048, June. 8 1993 Kuritzkes, D.R., Welles, S., Johnson, V.A., Crumpacker, C.S., De Japour, A.J. The ACTG 116B/117 Virology Resistance Team. ÅBaseline Prevale Clinical Significance of Zidovudine (ZDV) Resistance Mutations in HIV-1 Isolates From Patients in ACTG Protocol 116B/117. Third Workshop on Viral Washington, D.C., September. 7 1992 Japour, A.J., Kuritzkes, D., Johnson, V., Mayers, D., Beckett, L., Arduino, J.M., D'Aquilia, R., Crumpacker, C.S. Consensus Protocol to Measure An Clinical HIV-1 Isolates. VIII International Conference on AIDS, Amsterdam, Th Netherlands, Abstract #PoA 2484, July. 6 1992 Johnson, V., Balfour, H., Beckett, L., Cheseboro, B., Crumpacker, C., Haberzetti, C., Japour, A.J., Katzenstein, D., Kuritzkes, D., Mayers, D., McIntosh, K., Ran Reichman, R., Richman, D., Scott, W., D'Aquila, R., AIDS Clinica Virology Committee Virus Resistance Working Group. Inter-Laboratory Variability of Anti-HIV-1 Susceptibility Testing. VIII International Conference on AIDS, Amsterdam, The Netherlands, Abstract #PoA2310, July. 5 1992 Japour, A.J., Kim, L., Chatis, P.A., Beckett, L., Arduino, J.M., Ecto, L., Chapman, B., Crumpacker, C.S. Serial HIV-1 ZDV and DDI Susceptibility in a Cohort of Subjects Japour_CV_AUG-2014 P. 15 Enrolled in Three Antiviral Trials. VIII International Conferenc The Netherlands, Abstract #PoB3572, July. 4 1992 Japour, A.J., Mayers, D., Arduino, J.M., Beckett, L., Crumpacker, C.S. ZDV & ddI Susceptibility Correlates in Clinical HIV-1 Isolates. Infectious Diseases Society of America Annual Meeting, Anaheim, California. 3 1991 Japour, A.J., Chatis, P.A., Kim, L., Crumpacker, C.S. HIV Susceptibility Testing in AIDS Clinical Trials. Seventh International Conference on AIDS, Florence, Italy, June. 2 1991 Japour, A.J., Chatis, P.A., Eigenrauch, H., Kim, L., Crumpacker, C.S. ddI Potentiation by Ribavirin. Seventh International Conference on AIDS, Florence, Italy, June. 1 1990 Japour, A.J., Eigenrauch, H.A., Chatis, P.A., Crumpacker, C.S. AZT-Resistant HIV Detection by RNA-RNA Hybridization. Sixth International Conference on AIDS, San Francisco, California, USA. Abstract #F.A.336, June. Other Publications/Books Japour A., Massaro, M., Nordstrom D., Silberman C., Provost D., Phase IV trial, 1 2006 observational study or patient registry: Which? When? Why? at: http://www.ppdi.com 7. PRESENTED LECTURES AND PAPERS Invited Lectures No Date Venue, Date, SOVALDI¨ (sofosbuvir) Roundtable Discussion: Clinical Considerat 62 7/2014 Patient Management, Coral Gables, FL Transforming the Treatment Paradigm, Review of SOVALDI¨(sofosbuv Miami 61 4/2014 Beach, FL Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Palm Harbor, FL 60 3/2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Florida Center for 59 3/2014 Gastroenterology, Largo, FL Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, St. Petersberg, FL 58 3/2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, GastroHealth, Miami, 57 3/2014 FL Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Tampa, FL 56 2/2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Palm Beach, FL 55 1/2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Punta Gorda, FL 54 1/2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Savannah, GA 53 1/2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Orlando, FL 52 12/2013 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Miami Beach, FL 51 12/2013 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Bonita Springs, FL 50 12/2013 Hepatitis C: Past, Present, Future, Borinquen Medical Centers of Miami Dade, 49 11/2013 Miami, FL Hepatitis C Medications & Side Effects, Hepatitis C Support Group, Miami Beach, 48 9/2013 FL Hepatitis C: Past, Present, Future, Mount Sinai Medical Center Medical Grand 47 8/2013 Rounds CME Program, Miami Beach, FL Japour_CV_AUG-2014 P. 16 Treatment-Nave Adult Patient with Chronic HCV G1 Infection who has 46 7/2013 Compensated Liver Disease, Miami, FL Addressing Chronic Hepatitis C in Primary Care: Integrating Rec 45 6/2013 Recommendations, Borinquen Medical Center, Miami, FL Addressing Chronic Hepatitis C in Primary Care: Integrating Rec 44 5/2013 Recommendations, Family Care at Bardmoor, Largo, FL Addressing Chronic Hepatitis C in Primary Care: Integrating Reccal 43 5/2013 Recommendations, Indian Shores, FL Treatment-Nave Adult Patient with Chronic HCV G1 Infection who has 42 4/2013 Compensated Liver Disease, Fort Myers, FL TodayÈs Chronic Hepatitis C Patient: Viral/Patient Factors and P 41 4/2013 Disease Progression, Digestive Care Center, North Miami, FL Treatment-Nave Adult Patient with Chronic HCV G1 Infection who has 40 3/2013 Compensated Liver Disease, Macon, GA Addressing Chronic Hepatitis C in Primary Care: Integrating Rece 39 3/2013 Recommendations, Athens, GA Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 38 3/2013 Practice, Absolute Care, Atlanta, GA Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 37 2/2013 Practice, Tampa General Medical Group, Tampa, FL Treatment-Nave Adult Patient with Chronic HCV G1 Infection who has 36 2/2013 Compensated Liver Disease, Miami Beach, FL Treatment-Nave Adult Patient with Chronic HCV G1 Infection who has 35 1/2013 Compensated Liver Disease, Melbourne, FL TodayÈs Chronic Hepatitis C Patient: Viral/Patient Factors and P 34 1/2013 Disease Progression, Daytona, FL Advanced Liver Disease in Chronic HCV: Strategies to Help and M 33 12/2012 Patients, Liver Transplant Unit at Broward General Medical Center, Fort Lauderdale, FL Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 32 11/2012 Practice, Triple O Medical, Palm Beach, FL Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 31 11/2012 Practice, Central Indiana Gastroenterology Group, Indianapolis, IN Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 30 11/2012 Practice, Private Practice, Palm Beach, FL Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 29 11/2012 Practice, Gastroenterology Care Center, Miami, FL Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 28 10/2012 Practice, Digestie Medicine Associates, Miami, FL Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 27 10/2012 Practice, University of Maryland Medical Center, Baltimore, MD Current Treatments for Chronic HCV: Translating Clinical Studies 26 9/2012 Practice, St. Petersburg, FL Management of Chronic Hepatitis C Infection, One Patient at a Ti, West Palm 25 8/2012 Beach, FL Current Treatments for Chronic HCV: Translating Clinical Studies 24 7/2012 Practice, Long Beach, CA Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical 23 7/2012 Practice, Los Angeles, CA Japour_CV_AUG-2014 P. 17 Management of Chronic Hepatitis C Infection, One Patient at a Ti, Miami 22 5/2012 Beach, FL 21 5/2012 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Augusta, GA 20 9/2011 Jackson North Medical Center Obstetrics & Gynecology, September Hepatitis C Diagnosis and Treatment in Pregnant Women-New Directions in Hepatitis C treatment 19 8/2011 Jackson North Medical Center Radio Show, August 2011, Hepatitis C in the Community-Epidemiology, Diagnosis a& New Treatment Directions in Hepatitis 18 1/2011 Florida International University College of Medicine, Syphilis 17 10/2010 BioFlorida Annual Conference, Ft. Lauderdale, FL, Keynote Address, Policy Implications for An Evolving Biosciences and Health Care Industr 16 01/2010 Florida International University College of Medicine, Syphilis 15 11/2009 American Bar Association, AIDS Coordinating Committee, New HIV Infections in the United States. 14 12/2009 Florida International University College of Medicine, Infectious Diseases as Agents of Bioterrorism 13 02/2009 Northwestern University, Keynote Address, Alumni Dance Marathon The st HIV/AIDS Battle in the 21 Century. Cruise Line International Association, Miami, FL, Avian Influenza 12 11/2008 11 11/2007 Cruise Line International Association, Miami, FL, Avian Influenza 10 2007 Seatrade, Miami Beach, FL, Avian Influenza 9 2007 Miami Beach City Hall, Miami Beach, FL, Avian Influenza- History and Present Threat 8 08/2006 Centers for Disease Control, Florida department of health, Miami-Dade County Health Department, International Conference of Cruise Lines, Royal Caribbean Cruises Avian Influenza (H5N1 Business Continuity and Shipboard Preparedness Planning) 7 2006 International Conference of Cruise Lines, Avian Influenza- History and Present Threat 6 2000-2003 Academic Medical Centers in the US, Where Science Meets Ethics in Clinical Trials: The HIV/AIDS Paradigm 5 1996-2002 Harvard HIV CME Course, Antiviral Drug Resistance or Where Science Meets Ethics in Clinical Trials: The HIV/AIDS Paradigm 4 1995-2002 Infectious Diseases Training Program, Beth Israel-Deaconess Medical Center, Antiretroviral Therapy for HIV Disease 3 1992-1995 Harvard Medical School, Clinical Pharmacology & Therapeutics cou Molecular Structure of Drug-Resistant HIV-1 2 1990-1995 Beth Israel Hospital Medical Housestaff Lecture Series, Syphilis in the AIDS Era 1 1989-1995 Harvard Medical School, Infectious Diseases course 513MJ, Syphilis in the AIDS Era Oral Presentations at Conferences No Date Authors, Title, Venue Japour_CV_AUG-2014 P. 18 1 1998 Japour, A., Murphy, R., Hicks, C., Eron, J., Yetzer, E., Hammer, S., Orth, Safety & Efficacy of ABT-378/Ritonavir in Antiretroviral-Nave HIV Patients: th Preliminary Phase II Results. 12 World AIDS Conference, Geneva, Switzerland, June 28 Poster Presentations at Conferences by Fellows No Date Authors, Title, Venue 4 1997 Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Colson, A., Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Zorilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV- 1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, California, September 3 1997 Race, E., Adelson-Mitty, J., Barlam, T., and Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease I in th Patients with Advanced HIV-1 Disease. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 352 2 1997 Colgrove, R., Japour, A.J. Mathematical Modeling of Within-Patient Evolution of HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcriptase Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority th of Three-drug Over Two-drug Therapeutic Regimens. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 406 1 1997 Race, E., Reimann, K., Letvin, N. and Japour, A.J. Recurrence of Trimethoprim- Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease th Inhibitor (PRI) in Patients with Advanced HIV-1. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 535 8. FUNDED RESEARCH Project No Project Title Agency Dates External Funding as PI 10 A Double-blind, Randomized, Placebo-controlled, Amgen 2013 Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination with Statin Therapy in Patients with Clinically Evident Cardiovascular Disease 9 A Multi-Center, Prospective, Randomized, Double-Blind, Amarin Pharma, 2012-2013 Placebo-Controlled, Parallel-Group Study to Evaluate the Inc. Effect of AMR101 on Cardiovascular Disease and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) Amarin Pharma, Inc 8 SABA: A study of factors that affect adherence to HIV Miami-Dade 2007-2009 therapy and safer sex behaviors among women in the County Health Miami-Dade CountyÈs AIDS Drug Assistance Program Department AIDS Program 7 FOCUS: A study of factors that affect adherence to HIV Miami-Dade 2004-2007 Japour_CV_AUG-2014 P. 19 therapy and safer sex behaviors among men who have sex County Health with men in the Miami-Dade CountyÈs AIDS Drug Department AIDS Assistance Program. Program 6 Intravenous Infusion in HIV-Positive Patients Hybridon 1996 5 Maternal-Infant Transmission of ZDV-Resistant HIV-1 in NIH-NIAID 1995-1999 the Women and Infants Transmission Study 4 Maternal-Infant Transmission of ZDV-Resistant HIV-1 Pediatric AIDS 1994-1996 Foundation 3 HIV-1 Zidovudine and Didanosine Resistance Detection DuPont-NEN Life 1994-1996 Sciences 2 Drug Resistant HIV-1 RT-Molecular Structure and NIH-NIAID 1992-1996 Function 1 Detection of HIV RNA in Patients Blood American 1989-1992 Foundation for AIDS Research External Funding as Co-PI/Co-Investigator 3 Biological Response Toolkit for Florida Hospitals. Florida Department 2006-2007 of Health Development, production and training kit. (subcontract to Jackson Health System) 2 Harvard Advanced Technical Laboratory Adult AIDS NIH-NIAID 1995-1996 Clinical Trial Group 1 Harvard/Boston City Hospital AIDS Clinical Trial Group NIH-NIAID 1992-1996 Students/Fellows Funding/Fellowships Project No Project Title Agency Dates 1 Elizabeth Race, M.D. (Fellowship) Harvard/MIT 1996-1998 Health Sciences Clinical Investigator Training Program Technology Program 9. PROFESSIONAL HONORS, PRIZES AND FELLOWSHIPS Local No Date Honor 2 2013 Best of 2013- Best MD, Miami Sun Post, Miami, FL 1 2003 Key to the City of Miami Beach, City of Miami Beach, FL National No Date Honor PresidentÈs Award, Abbott Laboratories 3 2000 1992-1996 Physician-Scientist Award, National Institute of Allergy and Infectious Di 2 Japour_CV_AUG-2014 P. 20 1989-1992 Scholar for the American Foundation for AIDS Research 1 10. TEACHING List of courses taught at FIU Courses other than Student Research Labs Course Name Course Number Fall Spring Medical Students Microbes, Infection and BMS6300 2009-2013 Immunology 11. MENTORING (SCHOLARS AND STUDENTS) Medical Residents No Date Name, Affiliation, Project Title, Papers 2 1995 Amy Colson, Beth Israel Hospital, Medical Resident, Boston, MA Title: Maternal-Infant HIV Drug Resistance Transmission Publications: Welles, S.L., Pitt, J., Colgrove, R., McIntosh, K., Chung, P.H., Colson, A., Lockman, S., Fowler, M. G., Hanson, C., Landesman, S., Moye J., Zorrilla, C., Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant Transmission In the Women and Infant Transmission Study. AIDS 14:263-272 Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Colson, A., Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Rich, K., Zorilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, Ca September 1 1995 Shahin Lockman, Beth Israel Hospital, Medical Resident, Boston, Title: Maternal-Infant HIV Drug Resistance Transmission Publiccation: Welles, S.L., Pitt, J., Colgrove, R., McIntosh, K., Chung, P.H., Lockman, S., Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C., Zorrilla, C., Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant Transmission In the Women and Infant Transmission Study. AIDS 14:263-272 Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Col Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Rich, K., Zorilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, Ca September Japour_CV_AUG-2014 P. 21 Postdoctoral Fellows No Date Name, Affiliation, Project Title, Papers 4 1998 Scott Brun, Physician Rotation Program, Abbott Laboratories Prof Program Title: Phase I/II Clinical Research Studies in HIV Publications: Hicks, C., King, M., Brun, S., Real, K., Murphy, R., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Benson, M., Alb Kessler, H., Hsu, A. Bertz, R., Kempf, D., Japour, A., & Sun, E. ABT- 378/Ritonavir (ABT-378/R) in Antiretroviral Nave HIV + Patients: 48 Weeks. 7th European Conference on Clinical Aspects and Treatment of HIV Lisbon, Portugal, October 23-27 Bertz, R., Lam, W., Brun, S., Kumar, G., Fields, C., Orth, K., Jennings, J., Hsu, A., Granneman, R., Japour, A., Sun, E. Multiple-Dose Pharmacokinetics (PK) of th ABT-378/Ritonavir (ABT-378/r) in HIV+ Subjects. 39 ICAAC Conference on Antimicrobial Agents and Chemotherapy, September 26-29 Murphy, R., King, M., Brun, S., Orth, K., Hicks, C., Eron, J., Thommes, J., Gulick, R., Thompson, M., White, C., Benson, C., Hammer, S., Kessler, H., Bertz, R., Hsu, A., Kempf, D., Sun, E., Japour, A. ABT-378/ritonavir Therapy in th Antiretroviral-Nave HIV-I Infected Patients for 24 weeks. 6 Conference on Retroviruses and Opportunistic Infections, January 31 - February 4 3 1995-96 Robert Colgrove, Beth Israel Hospital, Boston, MA Title: Mathematical Modeling of HIV Drug Resistance Publication: Colgrove, R., Japour, A. A Combinatorial Ledge: Reverse Transcriptase Fidelity, Total Body Viral Burden, and the Implications of Multiple-Drug HIV Therapy for the Evolution of Antiviral Resistance. Antiviral Res 41:45-56 Colgrove, R., Japour, A.J. Mathematical Modeling of Within-Patient Evolution of HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcr Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear th Superiority of Three-drug Over Two-drug Therapeutic Regimens. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 406 Title: Maternal-Infant HIV Drug Resistance Transmission Publication: Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L., Japour, A.J. Selective Vertical Transmission of HIV-1 Antiretroviral Resistance Mutations. AIDS 12:2281-2288 Colgrove, R., Pitt, J., Japour, A., Welles, S. Evolutionary Hotspot around RT th Codon 215 Evolves During Zidovudine Exposure. 6 Conference on Retroviruses and Opportunistic Infections, January 31 - February 4 Colgrove, R., Pitt, J., Chung, P., Welles, S., Japour, A.J., Harvard Medical School, Boston, Massachusetts, Columbia University, and University of Minnesota, Minneapolis, Minnesota. Selective Vertical Transmissi-1 th Zidovudine Resistance Mutations. 5 Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois 2 1995-96 Jennifer Adelson-Mitty, Beth Israel Hospital, Boston, MA Title: HIV Immune Reconstituion Syndrome Publication: Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease I Japour_CV_AUG-2014 P. 22 in Patients with Advanced HIV-1 Disease. Lancet 351:252-255 1 1994-96 Elizabeth Race, Beth Israel Hospital, Boston, MA Title: HIV Immune Reconstituion Syndrome Publication: Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1 Disease. Lancet 351:252-255 Race, E., Reimann, K., Letvin, N. and Japour, A.J. Recurrence of Trimet- Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease th Inhibitor (PRI) in Patients with Advanced HIV-1. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 535 Race, E., Adelson-Mitty, J., Barlam, T., and Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) th in Patients with Advanced HIV-1 Disease. 4 Conference on Retroviruses and Opportunistic Infections, Washington, DC. 352 12. OTHER PROFESSIONAL ACTVITIES AND PUBLIC SERVICE SERVICE DETAILS Editorial Boards No Date Editorial Board 1 1995-96 Associate Editor, AIDS Clinical Care published by the Massachuse Society Journal Reviews No Date Reviewing Duties: Journal 6 2012 Future Virology- ad hoc 5 2002-03 Clinical Infectious Diseases- ad hoc 4 1995-03 AIDS- ad hoc 3 1995-2003 Journal of Infectious Diseases- ad hoc 2 1994-98 Journal of Clinical Microbiology- ad hoc 1 1994-2003 Journal of AIDS- ad hoc Grant Reviews No Date Agencies 1 1993-2010 Ad hoc Reviewer, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Conference Committees-AIDS Clinical Trials Group (ACTG) No Date Conference Information Assay Development Committee, Virology Quality Assurance Program -DAIDS 10 1996 NIH ACTG Adult Scientific Virology Committee, Core Member 9 1994-96 NIH ACTG Genotype Sequencing Swat Team, Core Member 8 1994-95 NIH ACTG HIV Resistance Screening Assay Swat Team, Chair 7 1994-95 Assay Development Committee, NIH AIDS Clinical Trial Group; Vice 6 1994-95 Beth Israel Hospital Clinical Research Center Scientific Advisor 5 1993-96 Japour_CV_AUG-2014 P. 23 NIH ACTG Primary Infection Committee Phase II/III Working Group 4 1993-95 NIH ACTG MT-2 Swat Team, Chair 3 1993-94 NIH ACTG Virology Committee 2 1990-95 NIIH ACTG HIV Resistance Working Group, Core Member 1 1990-93 Others No Date National Activities Hepatology SpeakerÈs Bureau, AbbVie, North Chicago, IL 23 2014 Hepatitis C SpeakerÈs Advisory Board, Bristol-Myers Squibb, Plainsboro, NJ 22 2014 HIV Clinical Advisory Board, Bristol-Myers Squibb, Plainsboro, NJ 21 2014 Hepatitis Clinical Advisory Board, Gilead Pharmaceuticals, Foste 20 2014 Hepatitis C SpeakerÈs Bureau, Janssen Pharmaceutical Company 19 2013- Present Hepatitis C SpeakerÈs Advisory Board, Boehringer Ingelheim GmbH 18 2013 Pharmaceuticals, Ridgefield, CT Hepatitis C SpeakerÈs Advisory Board-USA, Merck & Company, Blue Bell, PA 17 2011- Present Health Advisory Board, City of Miami Beach 16 2011-2013 Scientific Advisory Board, ImmunoGenetix, Inc., Lenexa, KS 15 2011- Present American Bar Association, AIDS Coordinating Committee, Health Ca, 14 2009- Washington, D.C. Present Homeless Committee, City of Miami Beach, Miami Beach, FL 13 2010 Republican Primary Candidate, State of Florida House of Representatives, District 12 2009-10 107 Cultural Arts Council, City of Miami Beach, Miami Beach, Fl 11 2007-10 Community Development Advisory Council, City of Miami Beach, Mia 10 2006 Florida Medical Association, Tallahassee, FL 9 2004-11 Miami Beach Bar Association, Miami Beach, FL 8 2006-08 Miami Beach Chamber of Commerce, Miami Beach, FL 7 2006-07 Scientific Advisory Board, Sequoia Pharmaceuticals, Inc., Gaithe 6 2004-06 Fine Arts Board, City of Miami Beach, Miami Beach, FL 5 2004-06 Scientific Advisory Board, PPD Inc. Government Group, Wilmington 4 2004-05 Miami Beach Latin Chamber of Commerce, Miami Beach, FL 3 2003-07 Board of Directors, Open Hand Chicago, Chicago, IL 2 1999-02 Blackstone - Franklin Square Neighborhood Association, Boston, MA 1 1989-96 University Service Year No Committees 1995-96 2 Scientific Director, Harvard-Thorndike General Clinical Research Center Molecular Core Laboratory 1995 1 Beth Israel Hospital- Harvard Medical School, HIV Endowment Fund Japour_CV_AUG-2014 P. 24 Japour_CV_AUG-2014 P. 25